TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8209277
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy following surgical resection for stages I, II, and IIIA disease
Study: 8209277
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy for locally advanced stages IIIA and IIIB disease
Study: 8209277
Drug: Chemotherapy for
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy for advanced stage IV disease
Study: 8209277
Drug: Biologic response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Biologic response modifiers (interferons, interleukins, colony-stimulating factors, monoclonal antibodies)
Study: 21474786
Drug: Oral testosterone
Normalized name: testosterone Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral testosterone undecanoate (TU)
Study: 24003041
Drug: Transdermal glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal glyceryl trinitrate (GTN; 5 mg/24 hours) for 7 days
Study: 21410294
Drug: Vandetanib 300
Normalized name: vandetanib 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vandetanib 300 mg with rifampicin 600 mg/day (Study A)
Study: 21410294
Drug: Vandetanib 300
Normalized name: vandetanib 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vandetanib 300 mg with itraconazole 200 mg/day (Study B)
Study: 12511526
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg OD losartan (LOS)
Study: 12511526
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg OD telmisartan (TEL)
Study: 12511526
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg OD losartan (LOS) + 20 mg OD lisinopril
Study: 12511526
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg OD telmisartan (TEL) + 20 mg OD lisinopril
Study: 12511526
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg OD losartan (LOS)
Study: 12511526
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg BID losartan (LOS)
Study: 12511526
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg OD telmisartan (TEL)
Study: 12511526
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg BID telmisartan (TEL)
Study: 8927672
Drug: Sertraline (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (selective serotonin reuptake inhibitor)
Study: 8927672
Drug: Imipramine (tricyclic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (tricyclic antidepressant)
Study: 10934454
Drug: Soluble human
Normalized name: Recombinant soluble human CD4
DrugBank: Recombinant soluble human CD4 (DB17782)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble human insulin
Study: 6348995
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 200 micrograms salbutamol followed immediately by 100 micrograms beclomethasone dipropionate
Study: 6348995
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 200 micrograms salbutamol followed by 100 micrograms beclomethasone dipropionate after a timed interval of more than five minutes
Study: 21562067
Drug: saxagliptin 5
Normalized name: sAXagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: saxagliptin 5 mg
Study: 30653843
Drug: Lutikizumab 100
Normalized name: Lutikizumab
DrugBank: Lutikizumab (DB16224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutikizumab 100 mg
Study: 30653843
Drug: Lutikizumab 25
Normalized name: Lutikizumab
DrugBank: Lutikizumab (DB16224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutikizumab 25 mg
Study: 30653843
Drug: Lutikizumab 200
Normalized name: Lutikizumab
DrugBank: Lutikizumab (DB16224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutikizumab 200 mg
Study: 30653843
Drug: Lutikizumab (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutikizumab (all doses)
Study: 30653843
Drug: Lutikizumab (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutikizumab (100 mg)
Study: 30463826
Drug: Systemic administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic administration of methotrexate
Study: 30463826
Drug: Local administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local administration of methotrexate
Study: 24905427
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy (ET) for 12 weeks (36 sessions)
Study: 15157261
Drug: 500 mL
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mL of water ingested 30 minutes before blood donation
Study: 2742942
Drug: Haloperidol (HAL)
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol (HAL) 10 mg oral test dose
Study: 2742942
Drug: Haloperidol (HAL)
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol (HAL) 5 mg orally twice daily for 7 days
Study: 2742942
Drug: Reduced Haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced Haloperidol (RHAL) 10 mg oral test dose
Study: 29223557
Drug: rosuvastatin 20
Normalized name: rosuvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 20 mg/d plus ω‐3 fatty acids 4 g/d (ROSUMEGA group)
Study: 29223557
Drug: rosuvastatin 20
Normalized name: rosuvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 20 mg/d (rosuvastatin group)
Study: 27769209
Drug: Family-based behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based behavioral social facilitation treatment (FBSFT), 17 weekly sessions at the OOC.
Study: 27769209
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (treatment as usual, TAU), monthly counselling sessions with primary health care nurse.
Study: 18332845
Drug: Haloperidol 0.5
Normalized name: haloperidol 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 0.5 mg TID, administered from up to 72 hours preoperatively until the third postoperative day
Study: 12641541
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro (0.2 Iu kg‐1) and vitamin C (1-g daily)
Study: 1947866
Drug: Day treatment
Normalized name: Pharmacist Clotrimazole 3 Day Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day treatment with community care
Study: 27333261
Drug: ABC (brief
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABC (brief advice and subsidized nicotine replacement therapy)
Study: 25148255
Drug: Warfarin induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin induction therapy
Study: 19914560
Drug: Surgery with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery with adjuvant therapy
Study: 19914560
Drug: Variations in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Variations in staging methods, surgical technique, radiotherapy technique, and chemotherapy regime
Study: 17324220
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract (EGb761) 240 mg
Study: 15644624
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg moclobemide daily for 6 months
Study: 29144805
Drug: Sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100 mg daily (SITA)
Study: 18432391
Drug: Self-administered TLFB
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered TLFB
Study: 18432391
Drug: Telephone-administered TLFB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-administered TLFB
Study: 14962967
Drug: Arthrographic distension
Normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthrographic distension with saline and steroid
Study: 12664761
Drug: Musculo‐skeletal medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Musculo‐skeletal medicine physician
Study: 9409315
Drug: Fradafiban (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fradafiban (dose producing > 80% fibrinogen receptor occupancy)
Study: 6761186
Drug: Aspirin 330
Normalized name: aspirin 330 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 330 mg
Study: 8518408
Drug: Toremifene (TOR)
DrugBank: Toremifene (DB00539)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Toremifene (TOR) 240 mg/day
Study: 8518408
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (TAM) 40 mg/day
Study: 8518408
Drug: Second line
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second line TOR or TAM treatment
Study: 11560537
Drug: QI-therapy (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: QI-therapy (n = 489 patients)
Study: 30818320
Drug: Implant systems
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant systems with the same surface and different design
Study: 26466947
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg add-on therapy to interferon β1b
Study: 26466947
Drug: Placebo add-on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo add-on therapy to interferon β1b
Study: 17509693
Drug: 10-session, protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-session, protocol continuation-phase therapy for 8 months
Study: 17509693
Drug: Control cohort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control cohort (stopped protocol treatment after the acute-phase)
Study: 15129317
Drug: Cyclosporin alone
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin alone (3.5 mg/kg/day) for three months
Study: 15129317
Drug: Cyclosporin (3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin (3.5 mg/kg/day) plus topical calcipotriol cream twice a day for three months
Study: 12472705
Drug: Midazolam 0.5
Normalized name: midazolam 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.5 mg x kg(‐1) with ketamine 1.8 mg x kg(‐1) (MK‐1)
Study: 12472705
Drug: Midazolam 0.5
Normalized name: midazolam 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.5 mg x kg(‐1) with ketamine 3 mg x kg(‐1) (MK‐2)
Study: 12472705
Drug: Midazolam 0.5
Normalized name: midazolam 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.5 mg x kg(‐1) (MD)
Study: 11748787
Drug: Olanzapine 5
Normalized name: olanzapine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 5 mg/day
Study: 24613032
Drug: Olanzapine 15
Normalized name: olanzapine 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 15 mg/day
Study: 17022791
Drug: Olanzapine 20
Normalized name: olanzapine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 20 mg/day
Study: 9659858
Drug: Olanzapine 30-40
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine 30-40 mg/day
Study: 9659858
Drug: Olanzapine 10-20
Normalized name: olanzapine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 10-20 mg/day
Study: 9659858
Drug: Olanzapine 30
Normalized name: olanzapine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 30 mg/day and higher
Study: 12212663
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg clonidine
Study: 12212663
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg yohimbine
Study: 21775918
Drug: Infusion with
Normalized name: Pureline Basic Infusion with Butterfly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion with 20 mg of nafamostat mesilate (group B)
Study: 21775918
Drug: Infusion with
Normalized name: Pureline Basic Infusion with Butterfly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion with 50 mg of nafamostat mesilate (group C)
Study: 21775918
Drug: Nafamostat mesilate
Normalized name: mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafamostat mesilate (20 mg) in low-risk patients
Study: 21775918
Drug: Nafamostat mesilate
Normalized name: mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafamostat mesilate (50 mg) in low-risk patients
Study: 21775918
Drug: Nafamostat mesilate
Normalized name: mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafamostat mesilate (20 mg) in high-risk patients
Study: 21775918
Drug: Nafamostat mesilate
Normalized name: mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafamostat mesilate (50 mg) in high-risk patients
Study: 18620801
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of topiramate and amitriptyline
Study: 16407642
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C and E supplementation (500 mg slow-release vitamin C and 272 IU vitamin E for 4 weeks)
Study: 16407642
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen (HBO) treatment (100% O2, 2.4 bar, 131 min)
Study: 14645636
Drug: Radiotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy with concurrent administration of cisplatin
Study: 14645636
Drug: Radiotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy with concurrent cisplatin
Study: 14645636
Drug: Concurrent radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent radiotherapy and cisplatin
Study: 7060821
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg penbutolol
Study: 7060821
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (propranolol or metoprolol with chlorthalidone)
Study: 30830964
Drug: Morphine-3-glucuronide (M3G)
Normalized name: MENTHOL GLUCURONIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine-3-glucuronide (M3G)
Study: 21041105
Drug: Morphine-6-glucuronide (M6G)
Normalized name: MENTHOL GLUCURONIDE
DrugBank: Morphine glucuronide (DB06409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine-6-glucuronide (M6G)
Study: 27989501
Drug: DFA-02 gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFA-02 gel (gentamicin 16.8 mg/mL and vancomycin 18.8 mg/mL)
Study: 27989501
Drug: DFA-02 gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFA-02 gel
Study: 11153970
Drug: Graded exposure
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Graded exposure in vivo treatment
Study: 3371389
Drug: metoprolol CR
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol CR (100 mg)
Study: 3371389
Drug: metoprolol SR
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: metoprolol SR (100 mg)
Study: 27651514
Drug: HYD intact
Approvals — FDA: no, EMA: no, PMDA: no
Description: HYD intact 60 mg
Study: 27651514
Drug: HYD chewed
Approvals — FDA: no, EMA: no, PMDA: no
Description: HYD chewed 60 mg
Study: 27651514
Drug: HYD milled
Approvals — FDA: no, EMA: no, PMDA: no
Description: HYD milled to fine particles 60 mg
Study: 27651514
Drug: Hydrocodone solution
Normalized name: hydrocodone Injectable Solution
DrugBank: Hydrocodone (DB00956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrocodone solution 60 mg
Study: 27651514
Drug: Hydrocodone solution,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone solution, HYD fine particles, HYD chewed, and HYD intact
Study: 21427643
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (CBT), up to 10 sessions for 12 weeks
Study: 17045826
Drug: Prednisolone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (10 mg bd)
Study: 17045826
Drug: Cilomilast (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilomilast (15 mg bd)
Study: 9304515
Drug: Multimodality therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodality therapy (chemotherapy and irradiation)
Study: 8492199
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of methylprednisolone given intravenously before operation in combination with orally administered rapid‐release and sustained‐release diclofenac preparations
Study: 2963645
Drug: Eleutherococcus senticosus
Normalized name: Eleutherococcus Senticosus Root
DrugBank: Eleuthero (DB14303)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eleutherococcus senticosus extract (10 ml, ethanolic preparation, 3 times daily for 4 weeks)
Study: 3076791
Drug: Subcutaneous terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous terbutaline
Study: 17127777
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ipratropium bromide and salbutamol
Study: 11391739
Drug: N‐0923 TDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: N‐0923 TDS 33.5 mg
Study: 11391739
Drug: N‐0923 TDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: N‐0923 TDS 67 mg
Study: 9164591
Drug: d-amphetamine 10
Normalized name: amphetamine / dextroamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine 10 mg in SOC
Study: 9164591
Drug: d-amphetamine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine (10 or 20 mg)
Study: 3618993
Drug: Pre-operative medication
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative medication
Study: 20210697
Drug: Anti-muscarinic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-muscarinic treatment alone (4 mgs of tolterodine orally for 12 weeks)
Study: 17620783
Drug: Oral fluid
Normalized name: cascara sagrada ORAL FLUID EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fluid therapy
Study: 15815811
Drug: Preservative-containing saline
Normalized name: CONTACT LENS SALINE,PRESERVED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preservative-containing saline solution during BTX-A injections in the upper face (n = 60)
Study: 15815811
Drug: Preservative-containing saline
Normalized name: CONTACT LENS SALINE,PRESERVED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preservative-containing saline solution during BTX-A injections in the neck (n = 15)
Study: 15815811
Drug: Preservative-containing saline
Normalized name: CONTACT LENS SALINE,PRESERVED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preservative-containing saline solution during BTX-A injections in the axillary region (n = 18)
Study: 15815811
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no preservative-containing saline solution) in the upper face (n = 60)
Study: 15815811
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no preservative-containing saline solution) in the neck (n = 15)
Study: 15815811
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no preservative-containing saline solution) in the axillary region (n = 18)
Study: 10425979
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of trazodone
Study: 2192369
Drug: Tulobuterol 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tulobuterol 2.0 mg
Study: 7042370
Drug: Penbutolol 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penbutolol 40 mg once a day
Study: 19918965
Drug: Intravaginal progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravaginal progesterone gel, 90 mg daily
Study: 9655769
Drug: 6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/kg fructose (placebo)
Study: 7658819
Drug: Cefuroxime (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime (4.5 g/day intravenously) from admission
Study: 7658819
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic treatment until clinical or microbiologically verified infection
Study: 2787297
Drug: Midazolam (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.2 mg/kg i.v.)
Study: 2787297
Drug: Diazepam (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.4 mg/kg i.v.)
Study: 820228
Drug: Low-dose intramuscular
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intramuscular insulin therapy
Study: 820228
Drug: High-dose insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose insulin therapy (intravenous and subcutaneous)
Study: 28007428
Drug: Topical 10%
Normalized name: urea topical 10% topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 10% azithromycin applied twice daily for 3 consecutive days
Study: 28007428
Drug: Placebo applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo applied twice daily for 3 consecutive days
Study: 28007428
Drug: Topical 10%
Normalized name: urea topical 10% topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 10% azithromycin
Study: 21701268
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline solution (HSS) with furosemide (250 mg) and moderate Na restriction (120 mmol)
Study: 21701268
Drug: Furosemide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (250 mg) without HSS and low Na diet (80 mmol)
Study: 19798725
Drug: rAAV1.tMCK.hSGCA gene
Approvals — FDA: no, EMA: no, PMDA: no
Description: rAAV1.tMCK.hSGCA gene therapy
Study: 26341174
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g tranexamic acid
Study: 15526307
Drug: Venlafaxine ER
Normalized name: Venlafaxine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine ER 75-150 mg/day
Study: 15526307
Drug: Citalopram 10-20
Normalized name: citalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 10-20 mg/day